Welcome to our new website. We have rebranded from Atnahs to Pharmanovia — read more
We attribute our success to the close partnerships we have formed across the board. We pride ourselves on our open and collaborative approach, and aim to be straightforward, honest and courteous in our dealings.
We develop and co-develop (in conjunction with CDMOs) niche (branded) generic medicines.
We license niche patent protected or Orphan Drug Designated (ODD) prescription medicines from speciality pharma.
We acquire “established” or “mature” off-patent branded prescription medicines from large cap and and speciality pharma.
We are transition experts: we specialise in the transfer of licences (Marketing Authorisations or MAs) and manufacturing (Technical Transfers or TTs). We have tried-and-tested methodologies and we have built a platform that can absorb and manage on an ongoing basis new acquisitions seamlessly.
We commit to continue the high-quality manufacturing and management of the iconic brands we acquire. At the same time, we aspire to breathe new life into these iconic brands, investing in them to make them stable and sustainable over the long-term.
As such, we consider ourselves a trusted and diligent caretaker of the brand into perpetuity.